Want to see HK:1681 full AI Analyst Report?
Consun Pharmaceutical Group Ltd. (1681) AI Stock Analysis
Consun Pharmaceutical Group Ltd.
(HKEX:1681)
The score is primarily supported by strong financial performance (high margins, strong ROE, and very low leverage) and an attractive valuation (low P/E and high dividend yield). This is partly offset by a mixed technical picture, with the stock still below longer-term moving averages and RSI near overbought, plus some uncertainty around the latest cash-conversion visibility.
Consun Pharmaceutical Group Ltd. (1681) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 12.54B
- Dividend Yield
- 5.11%
- Average Volume (3M)
- 1.72M
- Price to Earnings (P/E)
- 9.4
- Beta (1Y)
- 0.44
- Revenue Growth
- 15.05%
- EPS Growth
- 20.58%
- Country
- Hong Kong
- Employees
- 2,847
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Consun Pharmaceutical Group Ltd. Business Overview & Revenue Model
Company Description
Consun Pharmaceutical Group Limited operates as an investment holding company, primarily engaged in the research, development, manufacturing, and distribution of traditional Chinese medicines and sophisticated medical contrast agents throughout the P...
How the Company Makes Money
Consun Pharmaceutical Group primarily makes money by selling prescription pharmaceutical products in Mainland China. Its core revenue stream is product sales from its self-manufactured drug portfolio, with sales typically generated through (i) hospit...
Consun Pharmaceutical Group Ltd. Financial Statement Overview
Summary
Strong overall fundamentals driven by very high and durable profitability (gross margin ~74%–78%, net margin ~28%–32%), steady multi-year revenue and net income expansion, and a conservative balance sheet with improving low leverage (debt-to-equity ~0.25 to ~0.05) and consistently strong ROE (~21%–23%). The score is tempered by uneven free-cash-flow growth in prior years and reduced transparency around 2025 earnings-to-cash conversion ratios, plus a potentially volatile 2025 growth step that needs confirmation.
Income Statement
92Very PositiveBalance Sheet
94Very PositiveCash Flow
78Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.61B | 3.42B | 2.97B | 2.59B | 2.34B | 2.04B |
| Gross Profit | 2.89B | 2.67B | 2.24B | 1.92B | 1.76B | 1.53B |
| EBITDA | 1.35B | 1.22B | 1.04B | 963.06M | 791.76M | 733.17M |
| Net Income | 1.17B | 1.08B | 910.46M | 784.53M | 682.91M | 590.17M |
Balance Sheet | ||||||
| Total Assets | 6.83B | 6.41B | 5.85B | 5.51B | 4.89B | 4.36B |
| Cash, Cash Equivalents and Short-Term Investments | 4.04B | 3.95B | 3.87B | 3.58B | 3.04B | 2.43B |
| Total Debt | 229.43M | 213.01M | 267.17M | 511.53M | 460.18M | 610.97M |
| Total Liabilities | 1.77B | 1.56B | 1.46B | 1.59B | 1.45B | 1.45B |
| Stockholders Equity | 4.76B | 4.54B | 4.10B | 3.63B | 3.15B | 2.62B |
Cash Flow | ||||||
| Free Cash Flow | 1.54B | 1.14B | 977.99M | 766.41M | 896.09M | 627.29M |
| Operating Cash Flow | 1.61B | 1.21B | 1.09B | 818.97M | 947.68M | 725.54M |
| Investing Cash Flow | -1.76B | -2.15B | -186.91M | -231.77M | -368.80M | -298.31M |
| Financing Cash Flow | -749.35M | -711.74M | -729.26M | -280.10M | -342.20M | -166.66M |
Consun Pharmaceutical Group Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1681, the sentiment is Positive. The current price of 15.25 is above the 20-day moving average (MA) of 15.20, above the 50-day MA of 14.23, and above the 200-day MA of 14.63, indicating a bullish trend. The MACD of 0.32 indicates Positive momentum. The RSI at 55.35 is Neutral, neither overbought nor oversold. The STOCH value of 19.56 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1681.
Consun Pharmaceutical Group Ltd. Peers Comparison
Overall Rating
- HK:168182Outperform
HK:046056Neutral
HK:998956Neutral
HK:071954Neutral
HK:057052.75Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1681 | 82Outperform | HKD 12.54B | 9.36 | 25.10% | 5.11% | 15.05% | 20.58% |
| HK:0460 | 56Neutral | HKD 6.76B | 18.38 | 5.03% | 1.50% | 29.68% | ― |
| HK:9989 | 56Neutral | HKD 14.42B | 185.14 | 1.58% | 4.22% | 3.10% | -46.64% |
| HK:0719 | 54Neutral | HKD 8.28B | 37.23 | 4.32% | 3.22% | -0.52% | -37.60% |
| HK:0570 | 53Neutral | HKD 5.89B | -4.80 | -4.98% | 0.30% | -15.80% | -298.94% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:1681 | Consun Pharmaceutical Group Ltd. | 15.25 | 1.00 | 7.00% | |
| HK:0570 | China Traditional Chinese Medicine Holdings Co | 1.17 | -1.16 | -49.79% | |
| HK:0460 | Sihuan Pharmaceutical Holdings Group | 0.72 | -0.75 | -50.71% | |
| HK:9989 | Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H | 3.94 | -1.40 | -26.20% | |
| HK:0719 | Shandong Xinhua Pharmaceutical Company Limited Class H | 5.35 | -1.42 | -20.94% | |
| HK:2637 | Fujian Haixi Pharmaceuticals Co., Ltd. Class H | 139.30 | 18.50 | 15.31% |
Consun Pharmaceutical Group Ltd. Corporate Events
Consun Pharmaceutical Declares Interim Cash Dividend for First Half of 2026
Consun Pharmaceutical Group Limited, a Hong Kong-listed pharmaceutical company focused on the development and distribution of medical products, maintains its primary listing under stock code 01681 and uses Computershare Hong Kong Investor Services Li...
Consun Pharmaceutical Delivers Strong Interim Earnings and Raises Payout
Consun Pharmaceutical Group reported robust interim results for the six months ended 30 June 2026, with revenue rising 13.8% year-on-year to RMB1.78 billion and gross profit reaching RMB1.45 billion. Profit attributable to equity shareholders grew 19...
Consun Pharmaceutical Schedules Board Meeting to Review 2026 Interim Results
Consun Pharmaceutical Group has scheduled a board meeting for 26 August 2026 to review and approve its unaudited consolidated interim results for the six months ended 30 June 2026. The board will also decide on the publication of these interim result...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 28, 2026